RICCI, ANGELA DALIA
RICCI, ANGELA DALIA
Anti-EGFR monoclonal antibodies in advanced biliary tract cancer: A systematic review and meta-analysis
2020 Rizzo A.; Frega G.; Ricci A.D.; Palloni A.; Abbati F.; de Lorenzo S.; Deserti M.; Tavolari S.; Brandi G.
Are FGFR and IDH1-2 alterations a positive prognostic factor in intrahepatic cholangiocarcinoma? An unresolved issue
2023 Brandi G.; Deiana C.; Galvani L.; Palloni A.; Ricci A.D.; Rizzo A.; Tavolari S.
Assessment of the Risk of Nodal Involvement in Rectal Neuroendocrine Neoplasms: The NOVARA Score, a Multicentre Retrospective Study
2022 Ricci A.D.; Pusceddu S.; Panzuto F.; Gelsomino F.; Massironi S.; De Angelis C.G.; Modica R.; Ricco G.; Torchio M.; Rinzivillo M.; Prinzi N.; Rizzi F.; Lamberti G.; Campana D.
Atezolizumab in advanced hepatocellular carcinoma: Good things come to those who wait
2021 Rizzo A.; Ricci A.D.; Brandi G.
Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials
2022 Di Federico A.; Rizzo A.; Carloni R.; De Giglio A.; Bruno R.; Ricci D.; Brandi G.
Bayesian Analysis Supports Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
2021 Rizzo A.; Ricci A.D.; Brandi G.
Bone targeting agents in patients with metastatic prostate cancer: State of the art
2021 Mollica V.; Rizzo A.; Rosellini M.; Marchetti A.; Ricci A.D.; Cimadamore A.; Scarpelli M.; Bonucci C.; Andrini E.; Errani C.; Santoni M.; Montironi R.; Massari F.
Circulating tumor DNA in biliary tract cancer: Current evidence and future perspectives
2020 Rizzo A.; Ricci A.D.; Tavolari S.; Brandi G.
Combination therapy of dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer
2021 Rizzo A.; Ricci A.D.; Brandi G.
Combining immune checkpoint inhibitors with locoregional therapies in hepatocellular carcinoma
2022 Rizzo A.; Ricci A.D.; Brandi G.
Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: A meta-analysis
2021 Rizzo A.; Mollica V.; Santoni M.; Rosellini M.; Marchetti A.; Ricci A.D.; Grilli G.; Greco A.; Montironi R.; Ardizzoni A.; Massari F.
Detecting and targeting NTRK gene fusions in cholangiocarcinoma: news and perspectives
2021 Rizzo A.; Ricci A.D.; Brandi G.
DNA damage response alterations in gastric cancer: Knocking down a new wall
2021 Ricci A.D.; Rizzo A.; Brandi G.
Dose reduction and discontinuation of standard-dose regorafenib associated with adverse drug events in cancer patients: a systematic review and meta-analysis
2020 Alessandro Rizzo; Margherita Nannini; Marco Novelli; Angela Dalia Ricci; Valerio Di Scioscio; Maria Abbondanza Pantaleo
Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand?
2022 Riccardo Carloni, Alessandro Rizzo, Angela Dalia Ricci, Giorgio Frega, Alessandro Di Federico, Andrea Palloni, Mariacristina Di Marco, Gennaro Gadaleta-Caldarola, Giovanni Brandi
Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer
2021 Rizzo A.; Ricci A.D.; Brandi G.
Experimental HER2- targeted therapies for biliary tract cancer
2021 Rizzo A.; Ricci A.D.; Bonucci C.; Tober N.; Palloni A.; Frega G.; Brandi G.
FGFR inhibitors in elderly patients with advanced biliary tract cancer: an unsolved issue
2021 Rizzo A.; Ricci A.D.; Frega G.; Di Federico A.; Brandi G.
First-line immune checkpoint inhibitor-based combinations in unresectable hepatocellular carcinoma: current management and future challenges
2021 Rizzo A.; Ricci A.D.; Gadaleta-Caldarola G.; Brandi G.
Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives
2021 Rizzo A.; Ricci A.D.; Brandi G.